Atmosudigdo Indriwanto Sakidjan, Pranata Raymond, Lim Michael Anthonius, Henrina Joshua, Yonas Emir, Vania Rachel, Radi Basuni
Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.
Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia.
J Clin Exp Hepatol. 2021 Feb 8. doi: 10.1016/j.jceh.2021.01.007.
This systematic review and meta-analysis aimed to evaluate whether dyslipidemia affects the mortality and severity of COVID-19, we also aimed to evaluate whether other comorbidities influence the association.
A systematic literature search using PubMed, Embase, and EuropePMC was performed on 8 October 2020. This study's main outcome is a poor composite outcome, comprising of mortality and severe COVID-19.
There were 9 studies with 3,663 patients. The prevalence of dyslipidemia in this pooled analysis was 18% (4%-32%). Dyslipidemia was associated with increased composite poor outcome (RR 1.39 [1.02, 1.88], p=0.010; I: 56.7%, p=0.018). Subgroup analysis showed that dyslipidemia was associated with severe COVID-19 (RR 1.39 [1.03, 1.87], p=0.008; I: 57.4%, p=0.029). Meta-regression showed that the association between dyslipidemia and poor outcome varies by age (coefficient: -0.04, p=0.033), male gender (coefficient: -0.03, p=0.042), and hypertension (coefficient: -0.02, p=0.033), but not diabetes (coefficient: -0.24, p=0.135) and cardiovascular diseases (coefficient: -0.01, p=0.506). Inverted funnel-plot was relatively symmetrical. Egger's test indicates that the pooled analysis was not statistically significant for small-study effects (p=0.206).
Dyslipidemia potentially increases mortality and severity of COVID-19. The association was stronger in patients with older age, male, and hypertension.
CRD42020213491.
本系统评价和荟萃分析旨在评估血脂异常是否会影响新型冠状病毒肺炎（COVID-19）的死亡率和严重程度，我们还旨在评估其他合并症是否会影响这种关联。
于2020年10月8日使用PubMed、Embase和EuropePMC进行了系统的文献检索。本研究的主要结局是不良复合结局，包括死亡率和重症COVID-19。
共有9项研究，涉及3663例患者。在该汇总分析中，血脂异常的患病率为18%（4%-32%）。血脂异常与不良复合结局增加相关（风险比[RR]1.39[1.02,1.88]，p=0.010；I²：56.7%，p=0.018）。亚组分析显示，血脂异常与重症COVID-19相关（RR 1.39[1.03,1.87]，p=0.008；I²：57.4%，p=0.029）。荟萃回归显示，血脂异常与不良结局之间的关联因年龄（系数：-0.04，p=0.033）、男性（系数：-0.03，p=0.042）和高血压（系数：-0.02，p=0.033）而异，但不受糖尿病（系数：-0.24，p=0.135）和心血管疾病（系数：-0.01，p=0.506）影响。倒漏斗图相对对称。Egger检验表明，汇总分析对小研究效应无统计学意义（p=0.206）。
血脂异常可能会增加COVID-19的死亡率和严重程度。在老年、男性和高血压患者中，这种关联更强。
CRD42020213491。
